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Abstract
Background: To assess whether the agreement between fasting glucose and glycated proteins is affected by
chronic kidney disease (CKD) in a community-based sample of 1621 mixed-ancestry South Africans.
Methods: CKD was defined as an estimated glomerular filtration rate < 60 ml/min/1.73 m2. Fasting plasma glucose
and haemoglobin A1c (HbA1c) concentrations were measured by enzymatic hexokinase method and high-
performance liquid chromatography, respectively, with fructosamine and glycated albumin measured by
immunoturbidimetry and enzymatic method, respectively.
Results: Of those with CKD (n = 96), 79, 16 and 5% where in stages 3, 4 and 5, respectively. Those with CKD had
higher levels of HbA1c (6.2 vs. 5.7%; p < 0.0001), glycated albumin (15.0 vs. 13.0%; p < 0.0001) and fructosamine
levels (269.7 vs. 236.4 μmol/l; p < 0.0001), compared to those without CKD. Higher fasting glucose levels were
associated with higher HbA1c, glycated albumin and fructosamine, independent of age, gender, and CKD. However,
the association with HbA1c and glycated albumin differed by CKD status, at the upper concentrations of the
respective markers (interaction term for both: p ≤ 0.095).
Conclusion: Our results suggest that although HbA1c and glycated albumin perform acceptably under conditions
of normoglycaemia, these markers correlate less well with blood glucose levels in people with CKD who are not on
dialysis.
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Background
Chronic kidney disease (CKD) is estimated to affect
about 10% of the general adult population and is even
more prevalent in diabetic patients [1, 2]. Indeed, 20–
40% of individuals with diabetes have moderate to severe
CKD, ranking diabetes as the leading cause of end-stage
renal disease (ESRD) and an important risk factor for
morbidity and mortality in dialysis patients [3].
It is known that good glycaemic control predicts better
clinical outcomes for patients with diabetes, by limiting
morbidity and mortality associated with cardiovascular
complications and end-organ damage [4, 5]. Traditionally,
sequential measurements of blood glucose and/or haemo-
globin A1c (HbA1c) (reflecting glycaemic control of the
preceding 2–3months) have been used to monitor gly-
caemia in patients with diabetes [6]. However, appropriate
measures to accurately monitor glucose control in CKD pa-
tients remain to be established. Anaemia, which is very
common in patients with CKD [7], affects haemoglobin
metabolism and thus the level of HbA1c [8]. The predom-
inant cause of anaemia in CKD relates to failure of the kid-
neys to produce enough erythropoietin, accompanying the
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fall in glomerular filtration rate (GFR) [7]. Consequently,
decreased erythropoiesis leads to increased circulating aged
red blood cells (RBCs) and a progressive rise in HbA1c, un-
related to glycaemic control [7, 9]. Contrary, treatment with
an erythropoiesis-stimulating agent or iron, results in in-
creased circulating immature RBCs that have a shorter gly-
caemic exposure time for glycation to occur, resulting in
reduced HbA1c levels, with no significant change in mean
glucose levels [10]. There are also several other diseases,
prevalent in Africa, that affect the clinical utility of HbA1c
and for which alternative markers may be necessary, includ-
ing sickle-cell disease in the more endemic malaria prone
regions, as well as HIV/AIDS and tuberculosis [11, 12].
It has been suggested that the relationship between
HbA1c and blood glucose concentration is altered as the
GFR declines [9]. As such, several alternative indices of
glycaemia have been reported, including fructosamine and
glycated albumin (GA); both shown to accurately reflect
glycaemic control in patients with CKD as they are not
impacted by reduced kidney function [13–15]. Fructosa-
mine and GA have shorter half-lives than HbA1c, thus
reflecting very recent (1–3 weeks) glycaemic control [16],
potentially lessening the confounding effect of shortened
RBC survival or high RBC turnover. However, the effect of
CKD on the agreement between these indices of glycaemic
control has yet to be assessed in the African context;
where there is a high frequency of factors affecting HbA1c
[11, 12].
The aim of the present study was to determine
whether the agreement between fasting blood glucose
(FPG) levels and markers of chronic glycaemia exposure
(HbA1c, GA and fructosamine) are affected by reduced
kidney function in a community-based sample of mixed-
ancestry South Africans.
Methods
Study population and setting
Data from the Cape Town Vascular and Metabolic
Health (VMH) study [17], collected between February
2015 and November 2016, was used in the current
cross-sectional analysis. The initial sample included
1647 participants, however 26 participants were ex-
cluded due to missing data required to estimate kidney
function, including serum creatinine, age or gender. As
previously described [17], the participants in the study
were all South Africans of mixed-ancestry. The VMH
study was approved by the Research Ethics Committees
of the Cape Peninsula University of Technology (CPUT)
and Stellenbosch University (NHREC: REC—230,408–
014 and N14/01/003, respectively) and conducted fully
in accordance with the Declaration of Helsinki. As such,
procedures were fully explained in the native language
of the participant, and voluntarily signed written in-
formed consent was obtained.
Anthropometric measures and biochemical analysis
As described elsewhere, all interviews and measurements
were conducted on the campus of CPUT [18]. An-
thropometric measurements were obtained by standard
procedures performed three times and the average used
for the analysis. Body weight was measured with a cali-
brated Omron body fat meter HBF-511 digital bathroom
scale, height with a stadiometer, and waist circumference
(WC) was measured at the level of the narrowest part of
the torso, using a non-elastic tape measure. Body mass
index (BMI) was calculated by the standard BMI eq.
A standard oral glucose tolerance test (OGTT) was per-
formed by drawing a blood sample after an overnight fast, as
well as 2 h after a 75 g oral glucose load, to determine
plasma glucose and serum insulin concentrations [19]. All
blood samples were analysed by an ISO 15189 accredited
Pathology practice (PathCare, Reference Laboratory, Cape
Town, South Africa). As previously described [18], plasma
glucose levels were measured by enzymatic hexokinase
method (Beckman AU, Beckman Coulter, South Africa) and
serum insulin with a paramagnetic particle chemilumines-
cence assay (Beckman DXI, Beckman Coulter, South Africa).
HbA1c was analysed with high-performance liquid chroma-
tography (Biorad Variant Turbo, BioRad, South Africa),
whereas haemoglobin was measured on a Coulter LH 750
haematology analyzer (Beckman Coulter, South Africa) and
fructosamine was determined by immunoturbidimetry on an
ABX Pentra 400 autoanalyser (Horiba Medical, USA). Total
protein and albumin levels were measured using the Biuret
and colourmetric (using bromocresol purple) method, re-
spectively (Beckman AU, Beckman Coulter, South Africa).
GA (%) was determined with the quantLab® Glycated Albu-
min enzymatic assay (Werfen™, Italy). Serum creatinine was
measured by the modified Jaffe-Kinetic method (Beckman
AU, Beckman Coulter, South Africa). Kidney function was
calculated using the serum creatinine-based estimator of
glomerular filtration rate (eGFR), namely the 4-variable
Modification of Diet in Renal Disease (MDRD) equation
[20], with the ethnicity correction factor omitted. The reason
for the omission is based on the South African Renal Society
CKD guidelines promoting the inclusion of the correction
factor only in the case of black Africans.
Classification of kidney function and co-morbidities
The National Kidney Foundation Disease Outcomes
Quality Initiative (NKF-KDOQI) classification [21] was
used to classify CKD; with CKD (stage 3–5) defined as
an eGFR< 60ml/min/1.73 m2. Glucose levels were used
to group participants into glucose tolerance categories
according to the WHO criteria [22] as: (1) normal glucose
tolerance [FPG < 6.1mmol/l and 2-h glucose < 7.8mmol/
l]; (2) pre-diabetes including impaired FPG (IFG, 6.1 ≤
FPG < 7.0mmol/l), impaired glucose tolerance (IGT, 7.8 <
2-h glucose< 11.1mmol/l) and the combination of both;
George et al. BMC Nephrology           (2020) 21:32 Page 2 of 11
and (3) type 2 diabetes (T2D) (FPG ≥ 7.0 mmol/l and/or 2-
h glucose≥11.1mmol/l). In addition to the screen-
detected T2D, those with a history of previously diagnosed
T2D were also grouped as T2D. A BMI greater or equal
to 25 kg/m2 was classified as overweight and a BMI
greater or equal to 30 kg/m2 as obese. Anaemia was de-
fined based on the K/DOQI guidelines as haemoglobin
level < 13.5 g/dL for men and < 12 g/dL for women [23].
Statistical analysis
Participant characteristics were summarised as median
(25th–75th percentiles) or count and percentages. Group
comparisons were analysed by chi-square tests (categorical
variables) and Wilcoxon rank-sum tests (continuous vari-
ables). Correlations between FPG, HbA1c, GA, and fruc-
tosamine were evaluated using Spearman’s rank
correlation coefficients (rho, r). To test the significant dif-
ference between the Spearman correlation coefficients,
principles of the Steiger test were used. Robust multiple
linear regression models were used to assess the inde-
pendent association between FPG and the glycaemic indi-
ces, while adjusting for age, gender, CKD status and the
interaction between CKD status and the glycaemic
marker. Further adjustments were made, which included
the addition of BMI to the regression models for all the
glycaemic markers (Appendix Table 3, Model 1), and
haemoglobin (in the model for HbA1c) or serum albumin
(in the model for GA) (Appendix Table 3, Model 2). To
investigate the interaction between FPG and the glycaemic
markers dichotomised by CKD status, predictive margins
were estimated, and graphs plotted for each glycaemic
marker. The average marginal effect was also computed
from the predictive margins (annotated as dy/dx). Similar
analysis, as described above, were conducted in a sub-
group of participants with confirmed diabetes (n = 277)
(Appendix Tables 4, 5 and 6 and Appendix Figs. 3 and 4).
Statistical analyses were performed using STATA version
15 (Statcorp, College Station, TX) and statistical signifi-
cance was based on a p-value < 0.05, except for interaction
tests; which was set at 0.10. This modification of the alpha
level to 10% was to assess the effect modification, thus
evaluating the magnitude of the association between fast-
ing glucose and the markers of glycaemia by CKD status.
Results
The general participant characteristics, which have been
presented in some detail previously [18], are summarised in
Table 1. Briefly, in the sample of 1621 participants, 25.1%
were males, with a group median age of 51 years, and 6% of
the total sample had CKD (eGFR< 60ml/min/1.73m2). In
the group with CKD, 79.2, 15.6 and 5.2% presented with
stages 3, 4 and 5 CKD, respectively. Furthermore, CKD was
associated with older age (68 vs. 49 years; p < 0.0001), a lar-
ger WC (99.0 vs. 90.8 cm; p < 0.0001) and higher BMI (30.4
vs. 28.2 kg/m2; p = 0.0035), compared to the participants
without CKD. Only 19.8% of those with CKD were of nor-
mal weight, compared to 35.3% in those with normal kid-
ney function. Higher fasting and 2-h blood glucose (5.3 vs.
5.0mmol/l; p < 0.0001 and 7.4 vs. 6.0mmol/l; p < 0.0001,
respectively) and fasting and 2-h insulin levels (7.6 vs. 6.7
IU/l; p = 0.0328 and 58.8 vs. 37.3 IU/l; p = 0.0003, respect-
ively) were found in the CKD group compared to those
with normal kidney function. Consequently, 19.8 and 38.5%
of the CKD participants had IFG/IGT and T2D, respect-
ively. In addition, CKD was coupled with a lower haemo-
globin level (12.5 vs. 13.5 g/dL; p < 0.0001), compared to
those with normal kidney function, with 44.8% of the CKD
participants presenting with anaemia. The prevalence of an-
aemia increased with increasing CKD-stage, from 40.0% at
stage 3, to 77.8% at stages 4–5. Participants with CKD had
higher levels of HbA1c (6.2 vs. 5.7%; p < 0.0001); increasing
incrementally for each glycaemic group, namely normogly-
caemia [median (25th–75th percentile): 6.0 (5.7–6.2)], IFG/
IGT [median (25th–75th percentile): 6.2 (5.9–7.1)] and
T2D [median (25th–75th percentile): 7.3 (6.3–8.9)]. Simi-
larly, GA was also higher in those with CKD compared to
those without CKD (15.0 vs. 13.0%; p < 0.0001), with an in-
cremental increase from normoglycaemia [median (25th–
75th percentile): 14.1 (13.4–15.1)], to IFG/IGT [median
(25th–75th percentile): 15.3 (14.2–16.3)] and T2D [median
(25th–75th percentile): 17.7 (14.9–23.0)]. Finally, the same
increased levels of fructosamine was observed in those with
CKD with normoglycaemia [median (25th–75th percentile):
245.9 (221.7–363.6)], IFG/IGT [median (25th–75th per-
centile): 282.3 (248.1–309.5)] and T2D [median (25th–75th
percentile): 285.5 (269.7–356.9)], with fructosamine levels
higher in those with CKD compared to those with normal
kidney function (269.7 vs. 236.4 μmol/l; p < 0.0001). Serum
albumin levels were similar in those with CKD compared
to those without CKD (4.25 vs 4.20 g/dL; p = 0.0601).
The correlation between FPG and HbA1c, GA, and fruc-
tosamine, with the regression line by CKD status, are shown
in Fig. 1. In the overall sample (data not shown), FPG was
positively associated with HbA1c, GA and fructosamine (r=
0.59, r= 0.44 and r= 0.52, respectively; p < 0.0001 for all);
with the FPG-HbA1c association being significantly stronger
than the FPG-GA (p= 0.0062) or FPG-fructosamine associ-
ation (p < 0.0001). When the correlations were analyzed by
CKD status, in both groups, FPG was positively associated
with HbA1c (r= 0.57 and r= 0.64, without CKD and with
CKD, respectively; p < 0.0001 for both), GA (r= 0.44 and
r= 0.51, respectively; both p < 0.0001) and fructosamine (r=
0.52 and r= 0.55, respectively; both p < 0.0001 for both), and
this association was similar for those with and without CKD
(p= 0.642; p= 0.149 and p= 0.312, for HbA1c, GA and fruc-
tosamine respectively). Similar results were found in the
sub-group of participants with diagnosed diabetes (Appen-
dix Fig. 3). As such, FPG was positively associated with
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HbA1c, GA and fructosamine in those with and without
CKD (p < 0.05 for all), with this correlation being similar for
people with and without CKD (p= 0.158; p= 0.274 and p=
0.110, for HbA1c, GA and fructosamine respectively).
The association between FPG levels and the glycaemic in-
dices, adjusting for age, gender, CKD status and the
interaction between CKD status and the glycaemic marker
are presented in Table 2, with the interaction dichotomized
by CKD status, presented in Fig. 2. Further adjustments for
BMI and total haemoglobin or serum albumin are presented
in Appendix Table 3, Models 1 and 2, respectively). Higher
FPG levels were associated with higher HbA1c, GA and
Table 1 Clinical characteristics of the study population overall and by CKD status
Variables Total (n = 1621) Without CKD (n = 1525) CKD (n = 96) p-value
Age (years) 51 (37–61) 49 (36–59) 68 (62–73.5) < 0.0001
Gender (n,% male) 406 (25.1) 378 (25.4) 19 (19.8) 0.221
Anthropometry
WC (cm) 91.5 (78.1–103.2) 90.8 (77.5–102.8) 99.0 (89.0–105.8) < 0.0001
BMI (kg/m2) 28.3 (22.8–34.1) 28.2 (22.5–34.1) 30.4 (26.0–36.1) 0.0035
Biochemical analysis and calculations
Fasting blood glucose (mmol/l) 5.0 (4.6–5.7) 5.0 (4.6–5.6) 5.3 (5.0–7.1) < 0.0001
2-h glucose (mmol/l) 6.0 (4.9–7.6) 6.0 (4.8–7.5) 7.4 (6.1–9.2) < 0.0001
Fasting insulin (IU/l) 6.7 (4.2–11.0) 6.7 (4.2–10.9) 7.6 (5.1–12.1) 0.0328
2-h insulin (IU/l) 37.9 (20.5–70.9) 37.3 (19.8–69.7) 58.8 (29.5–105.2) 0.0003
Haemoglobin (g/dL) 13.5 (12.6–14.4) 13.5 (12.6–14.5) 12.5 (11.15–13.45) < 0.0001
HbA1c (%) (n = 1610) 5.8 (5.4–6.3) 5.7 (5.4–6.2) 6.2 (5.9–7.1) < 0.0001
Albumin (g/dL) 4.24 (4.04–4.41) 4.25 (4.05–4.42) 4.20 (3.99–4.31) 0.0601
GA (%) (n = 1504) 13.1 (12.1–14.4) 13.0 (12.1–14.2) 15.0 (13.7–17.7) < 0.0001
Fructosamine (μmol/l) (n = 636) 238.8 (221.1–263.7) 236.4 (220.1–259.1) 269.7 (234.1–304.0) < 0.0001
Creatinine (μmol/l) 59.0 (52.0–70.0) 59.0 (51.0–68.0) 105.5 (89.0–137.5) < 0.0001
eGFR (ml/min/1.73m2) – 104.4 (88.4–121.5) 48.5 (34.1–56.2) < 0.0001
Co-morbidities
Anaemia (n, %) 311 (19.2) 268 (17.6) 43 (44.8) < 0.0001
BMI categories (n, %) 0.008
Normal weight 557 (34.4) 538 (35.3) 19 (19.8)
Overweight 372 (23.0) 345 (22.6) 27 (28.1)
Obese 692 (42.7) 642 (42.1) 50 (52.1)
Glucose tolerance categories (n, %) < 0.0001
Normal glucose tolerance 1048 (64.7) 1009 (66.2) 39 (40.6)
IFG/IGT 281 (17.3) 262 (17.2) 19 (19.8)
T2D 277 (17.1) 240 (15.7) 37 (38.5)
Data is presented as median (25th–75th percentiles) and percentages
WC waist circumference, BMI body mass index, HbA1c glycated haemoglobin, GA glycated albumin, eGFR estimated glomerular filtration rate, IFG/IGT impaired
fasting glucose and impaired glucose tolerance, T2D type 2 diabetes mellitus
Fig. 1 Correlation between fasting glucose, a HbA1c, b GA and c fructosamine. Data is presented as Spearman’s correlation coefficient (r) and p-
value. Without CKD, eGFR >60ml/min/1.73m2; CKD, eGFR <60ml/min/1.73m2
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fructosamine levels, independent of age, gender, and CKD
status (p < 0.0001 for all). Further, the association between
FPG and HbA1c as well as GA levels, differed by CKD sta-
tus (interaction; p= 0.030 and p= 0.095, respectively), in
contrast to the association between FPG and fructosamine,
which was similar for those with and without CKD (inter-
action p= 0.851) (Table 2). As such, at HbA1c levels ≥8%
and GA levels ≥35%, individuals with CKD had higher FPG
than those without CKD (p < 0.10) (Fig. 2a and b). Similar
results for the association between FPG and HbA1c was
found in the sub-group of participants with diagnosed dia-
betes (interaction; p = 0.054), but the FPG-GA and FPG-
fructosamine associations were similar for the two groups
(interaction; p > 0.215 for both) (Appendix Tables 4, 5 and
6, Model 1). Further adjustment of the regression analysis
for BMI did not alter the association between FPG and
HbA1c, GA or fructosamine (Appendix Table 3, Model 1).
In addition, HbA1c and GA were associated with FPG, inde-
pendent of total haemoglobin and serum albumin, respect-
ively, and adjusting for total haemoglobin had no effect on
the effect size of the interaction term CKD*HbA1c. How-
ever, when including total serum albumin to the GA model,
the effect size of the interaction term CKD*GA was no lon-
ger significant (Appendix Table 3, Model 2).
Discussion
The aim of this study was to determine whether the
agreement between FPG and markers of chronic
glycaemia exposure were affected by reduced kidney
function in a mixed-ancestry African population who
were not receiving dialysis. This study found that FPG
correlated most closely with HbA1c, compared to the al-
ternative markers of chronic glycaemia, however the as-
sociation between FPG and HbA1c as well as with GA
differed by CKD status, particularly at the higher con-
centration of these markers.
A few studies have explored the association between
FPG and measures of chronic glycaemia exposure
(HbA1c, GA and fructosamine), with a limited number
having investigated this association in those with less se-
vere CKD (stages 3 and 4) [24]. In clinical practice, it is ac-
cepted that glycaemic control is best assessed by HbA1c
in the general diabetic population. However, studies have
demonstrated that HbA1c underestimates and inaccur-
ately reflects long-term glycaemic control in patients with
severe CKD, including those with pre-dialysis ESRD [25]
and dialysis-dependent CKD [26, 27]. This mechanism for
falsely lower HbA1c levels in people with severe CKD can
be explained by shortened red blood cell survival in this
patient group [7–9]. Yet, what studies do not show is that
even during the earlier stages of kidney dysfunction, where
the individual might not be aware of their condition,
HbA1c assays inaccurately reflect glycaemia. Indeed, in
the current study, of which 95% of the participants were
in stages 3 and 4 CKD, we found that although FPG corre-
lated well with HbA1c, it underestimated glycaemic
Table 2 Adjusted association between fasting glucose and markers of glycaemia (HbA1c, glycated albumin and fructosamine)
HbA1c Glycated albumin Fructosamine
β 95% CI p β 95% CI p β 95% CI p
Marker of glycaemia 1.52 1.47 to1.57 < 0.0001 0.46 0.44 to 0.47 < 0.0001 0.03 0.03 to 0.04 < 0.0001
Age −0.04 −0.10 to − 0.01 0.105 − 0.03 −0.02 to 0.09 0.267 −0.03 − 0.10 to 0.10 0.539
Gender 0.05 −0.13 to 0.23 0.579 −0.32 −0.50 to − 0.13 0.001 −0.34 − 0.69 to 0.00 0.052
CKD −1.22 −2.55 to 0.10 0.071 −1.00 −2.02 to 0.01 0.053 −0.09 −2.04 to 1.86 0.927
CKDxGM 0.21 0.02 to 0.39 0.030 0.05 −0.01 to 0.11 0.095 0.00 −0.01 to 0.01 0.815
Adjusted R2 0.72 0.73 0.67
Data represents β-coefficients, 95% confidence interval, p-value and adjusted-R2
CKD chronic kidney disease, CKDxGM interaction between CKD and the respective glycaemic marker, HbA1c haemoglobin A1c
Fig. 2 Adjusted association between fasting glucose and markers of glycaemia, a HbA1c, b glycated albumin, c fructosamine, dichotomized by CKD
status. Data is presented as (1) linear predictive margins for those with CKD (dashed line) and those without CKD (solid line) with 95% CI and (2) the
average marginal effect (dy/dx), 95% CI and p-value indicating association between FPG levels and markers of glycaemia, for those with and without CKD
George et al. BMC Nephrology           (2020) 21:32 Page 5 of 11
control at the higher concentration of the marker (diabetic
range) in participants with CKD. This finding was further
confirmed in a smaller sub-group of individuals with T2D,
in which the adjusted association between FPG and
HbA1c differed by CKD status (Appendix Table 4).
Due to the strong link between HbA1c and haemoglobin
metabolism, alternative markers of glycaemic control have
been proposed for diabetic patients with CKD [25, 28].
These include GA and fructosamine, which have both been
shown to accurately reflect glycaemic control [13–15, 25].
Most of these studies were however conducted in patients
with CKD receiving either haemodialysis or peritoneal dia-
lysis [13, 27, 29]. It is therefore still not fully known whether
these alternative markers are similarly valid to assess gly-
caemic control in individuals presenting in the earlier stages
of kidney dysfunction, prior to receiving dialysis. GA levels
are readily influenced by factors associated with albumin
turnover [16], and might therefore not appropriately predict
glycaemic control in patients with earlier stages of CKD
and not on dialysis. Indeed, it has been shown that individ-
uals with CKD, typically with overt albuminuria, have GA
values that are lower relative to FPG levels (as found in the
current study), typically because of increased albumin me-
tabolism [16]. On the contrary, in patients on dialysis, albu-
minuria is significantly lower compared to pre-dialysis,
potentially mitigating this effect of albumin metabolism
[30], thus more accurately reflecting glycaemia in these pa-
tients [13, 27, 29]. In addition, a negative association exists
between GA and BMI [31, 32], which also potentially af-
fects the usefulness of GA as a marker of glycaemia, par-
ticularly with the high global prevalence of obesity [33].
Previous studies have reported lower serum GA levels in
both non-diabetic obese and obese T2D patients [31, 32].
In these studies, it was found that GA levels in non-diabetic
obese individuals were influenced by factors other than
plasma glucose, such as inflammation associated with in-
creased BMI [31]. However, in obese T2D patients GA
levels were greatly influenced by insulin levels [34]. Even
thought, half the individuals in the current study had a BMI
> 30 kg/m2, further adjustment of the regression analysis
for BMI, did not affect the association between FPG and
GA in this sample (Appendix Table 3, Model 1). However,
the extent to which BMI affects GA in those with CKD re-
quires further investigation. Fructosamine, has also been
proposed as an alternative marker in individuals with CKD,
as like GA, it is not affected by haemoglobin-related factors
or erythrocyte turnover [28]. However, contradictory results
have been reported with respect to the association between
FPG and fructosamine in individuals with CKD [35, 36].
Most reported correlation coefficients between FPG and
fructosamine, though significant, have been very low and
have therefore not allowed fructosamine to be implemented
as a reliable marker in glycaemic control. The present study
also showed a weaker correlation between FPG and
fructosamine, compared to those found for HbA1c and
GA. Yet, the relationship between FPG and fructosamine
was unaffected by CKD status, portraying it as a potential
marker of long-term glycaemic control. With that said,
whether fructosamine complements or outperforms HbA1c
in individuals with CKD requires further investigation.
Our study has a few limitations, such as the high female
to male participation, however this is a common trend in
South African population studies, and we do correct for
gender in all our analysis. According to NKF-KDOQI
guidelines, CKD is defined as an eGFR < 60ml/min/1.73
m2 for ≥3months and/or increased urinary albumin ex-
cretion (≥30mg/24 h) [21]. For the current study and vari-
ous other population-based prevalence and association
studies in the field of CKD epidemiology, CKD was based
on a single time-point creatinine assessment and not on
repeated measurements. Further, our study did not in-
clude estimates of albuminuria, which is important in the
interpretation of eGFR greater that 60ml/min/1.73m2.
There were also very few participants in the very advanced
stages of CKD (stage ≥4). We also used a single FPG
measurement, which is useful for glucose tolerance
screening, however for glucose control assessment, serial
measurements of blood glucose would have been more
appropriate. Other limitations include, small sample size
for fructosamine (n = 636; 6.8% with CKD) and not meas-
uring potential confounding factors, such as protein and
caloric intake. Even though our results should be inter-
preted cautiously in light of the data limitations, we are
not aware of other studies that have assessed the agree-
ment between FPG and HbA1c, GA and fructosamine in
individuals with and without CKD, over the complete gly-
caemic spectrum, in a population-based setting in Africa,
specifically individuals of mixed-ancestry. Furthermore,
our study consisted of a large sample size and we studied
a community with a high burden of obesity and T2D, re-
flective of the current burden in Africa [37].
Conclusions
Though HbA1c and GA perform acceptably under condi-
tions of normoglycaemia, our findings suggest that these
markers significantly underestimate true glycaemic levels
in people with CKD, not on dialysis. Our results suggest
that fructosamine may potentially be a more reliable
marker of glycaemic levels in those with CKD with ele-
vated FPG. Yet, a limitation to the use of fructosamine as
glycaemic marker is that there is no established clinical
cut-point for fructosamine and this assay is not standar-
dised across instruments. Therefore, further large-scale
studies are needed to demonstrate whether fructosamine
has prognostic power to predict adverse clinical outcomes
in those with CKD, above that of HbA1c, as there are
presently no clinical trial data demonstrating its effective-
ness as a glycaemic target in those with moderate CKD.
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Appendix
Fig. 3 Correlation between fasting glucose, (A) HbA1c, (B) GA and (C) fructosamine in those with confirmed type 2 diabetes. Data is presented as
Spearman’s correlation coefficient (r) and p-value. Without CKD, eGFR >60ml/min/1.73m2; CKD, eGFR <60ml/min/1.73m2
Fig. 4 Adjusted association between fasting glucose and markers of glycaemia, (A) HbA1c, (B) glycated albumin, (C) fructosamine, dichotomized
by CKD status, in those with confirmed type 2 diabetes. Data is presented as (1) linear predictive margins for those with CKD (dashed line) and
those without CKD (solid line) with 95% CI and (2) the average marginal effect (dy/dx), 95% CI and p-value indicating association between FPG
levels and markers of glycaemia, for those with and without CKD.
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Table 3 Adjusted association between fasting blood glucose and markers of glycaemia (HbA1c, glycated albumin and fructosamine)
MODEL 1 MODEL 2
β 95% CI p β 95% CI p
HbA1c 1.51 1.46 to 1.57 < 0.000 1.51 1.46 to 1.56 < 0.0001
Age −0.00 −0.01 to 0.00 0.093 0.00 −0.01 to 0.00 0.126
Gender 0.07 −0.12 to 0.25 0.471 0.01 −0.18 to 0.20 0.933
CKD −1.24 −2.56 to 0.08 0.066 −1.25 −2.57 to 0.07 0.064
CKDxHbA1c 0.21 0.21 to 0.40 0.027 0.22 0.03 to 0.40 0.023
BMI −0.00 − 0.01 to 0.01 0.526 – – –
Haemoglobin – – – 0.03 −0.02 to 0.08 0.230
Adjusted R2 0.72 0.72
Glycated albumin 0.45 0.44 to 0.47 < 0.0001 0.46 0.43 to 0.48 < 0.0001
Age −0.01 −0.06 to 0.04 0.689 0.00 −0.01 to 0.01 0.549
Gender −0.06 −0.24 to 0.13 0.540 −0.19 − 0.49 to 0.11 0.208
CKD −1.19 −2.17 to −0.21 0.018 −0.26 − 1.54 to 1.01 0.685
CKDxGA 0.06 0.00 to 0.12 0.033 0.01 −0.06 to 0.08 0.719
BMI 0.04 0.03 to 0.05 < 0.0001 – – –
Albumin – – – −0.04 −0.08 to − 0.00 0.037
Adjusted R2 0.74 0.71
Fructosamine 0.03 0.03 to 0.04 < 0.0001
Age −0.07 −0.16 to 0.03 0.167
Gender 0.01 −0.35 to 0.36 0.970
CKD −0.64 −2.53 to 1.25 0.506
CKDxFructosamine 0.00 −0.00 to 0.01 0.413
BMI 0.05 0.03 to 0.07 < 0.0001
Adjusted R2 0.69
Data represents β-coefficients, 95% confidence interval, p-value and adjusted-R2. HbA1c, glycated haemoglobin; BMI, body mass index; CKD, chronic kidney dis-
ease; CKDxHbA1c; interaction between CKD and HbA1c; CKDxGA; interaction between CKD and glycated albumin; CKDxFructosamine; interaction between CKD
and fructosamine; GA, glycated albumin. Model 1: glycaemic marker + age + gender + CKD status + interaction term + BMI; Model 2: glycaemic marker + age +
gender + CKD status + interaction term + haemoglobin (HbA1c model) or serum albumin (GA model)
Table 4 Adjusted association between fasting blood glucose and HbA1c in those with confirmed type 2 diabetes
MODEL 1 MODEL 2 MODEL 3
β 95% CI p β 95% CI p β 95% CI p
HbA1c 1.55 1.40 to 1.70 < 0.0001 1.56 1.41 to 1.71 < 0.0001 1.55 1.40 to 1.70 < 0.0001
Age − 0.04 −0.07 to − 0.01 0.018 − 0.04 −0.07 to − 0.01 0.014 −0.04 − 0.07 to − 0.01 0.018
Gender − 0.06 −0.96 to 0.84 0.898 −0.02 − 0.90 to 0.93 0.971 − 0.11 − 1.07 to 0.96 0.830
CKD −3.00 −7.02 to 1.01 0.142 −2.91 −6.93 to 1.10 0.154 −2.98 −7.00 to 1.04 0.145
CKDxHbA1c 0.47 −0.01 to 0.96 0.054 0.47 −0.01 to 0.95 0.056 0.48 −0.00 to 0.96 0.050
BMI – – – 0.01 −0.04 to 0.06 0.595 – – –
Haemoglobin – – – – – – 0.04 −0.19 to 0.28 0.718
Adjusted R2 0.66 0.66 0.66
Data represents β-coefficients, 95% confidence interval, p-value and adjusted-R2. HbA1c, glycated haemoglobin; BMI, body mass index; CKD, chronic kidney dis-
ease; CKDxHbA1c, interaction between CKD and HbA1c. Model 1: HbA1c + age + gender + CKD + CKDxHbA1c; Model 2: Model 1 + BMI. Model 3:
Model 1 + haemoglobin
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Table 5 Adjusted association between fasting blood glucose and glycated albumin in those with confirmed type 2 diabetes
MODEL 1 MODEL 2 MODEL 3
β 95% CI p β 95% CI p β 95% CI p
Glycated albumin 0.40 0.35 to 0.44 < 0.0001 0.41 0.36 to 0.45 < 0.0001 0.38 0.31 to 0.45 < 0.0001
Age −0.05 − 0.08 to − 0.02 0.005 − 0.05 −0.08 to − 0.01 0.006 −0.07 − 0.12 to − 0.02 0.009
Gender − 0.51 −1.47 to 0.44 0.291 − 0.23 − 1.18 to 0.72 0.635 0.04 − 1.33 to 1.42 0.950
CKD −1.57 −4.52 to 1.38 0.296 −1.66 −4.54 to 1.23 0.260 −1.79 −4.78 to 3.19 0.695
CKDxGA 0.09 −0.05 to 0.22 0.215 0.09 −0.04 to 0.23 0.169 0.06 −0.10 to 0.23 0.448
BMI – – – 0.07 0.02 to 0.13 0.005 – – –
Serum albumin – – – – – – −0.21 −0.39 to − 0.02 0.027
Adjusted R2 0.62 0.64 0.59
Data represents β-coefficients, 95% confidence interval, p-value and adjusted-R2. BMI, body mass index; CKD, chronic kidney disease; GA, glycated albumin;
CKDxGA, interaction between CKD and GA. Model 1: GA + age + gender + CKD + CKDxGA; Model 2: Model 1 + BMI. Model 3: Model 1 + serum albumin
Table 6 Adjusted associations between fasting blood glucose and fructosamine in those with confirmed type 2 diabetes
MODEL 1 MODEL 2
β 95% CI p β 95% CI p
Fructosamine 0.03 0.02 to 0.04 < 0.0001 0.03 0.02 to 0.04 < 0.0001
Age − 0.08 −0.14 to − 0.03 0.003 −0.07 − 0.13 to − 0.02 0.008
Gender − 0.08 −1.51 to 1.36 0.916 0.23 −1.19 to 1.65 0.750
CKD −0.47 −5.61 to 4.67 0.857 −1.39 −6.47 to 3.69 0.589
CKDxFruc 0.00 −0.01 to 0.02 0.586 0.01 −0.01 to 0.02 0.369
BMI – – – 0.08 0.01 to 0.16 0.035
Adjusted R2 0.56 0.57
Data represents β-coefficients, 95% confidence interval, p-value and adjusted-R2. BMI, body mass index; CKD, chronic kidney disease; CKDxfruc, interaction be-
tween CKD and fructosamine. Model 1: fructosamine + age + gender + CKD + CKDxFruc; Model 2: Model 1 + BMI
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